Results 71 to 80 of about 424 (108)

Droxidopa for orthostatic hypotension

Journal of Hypertension, 2016
The systematic review and meta-analysis aims to determine the efficacy and safety of droxidopa in the treatment of orthostatic hypotension, following its recent approvals in the United States.MEDLINE, EMBASE, PubMed, Cochrane Controlled Trials Register, Web of Science, ProQuest, and the WHO Clinical Trials Registry were searched.
Maw Pin Tan, Julia L. Newton, James Frith, Victoria Strassheim   +3 more
openaire   +3 more sources

Droxidopa for Vasopressor Weaning in Critically Ill Patients with Persistent Hypotension: A Multicenter, Retrospective, Single-Arm Observational Study

Journal of Intensive Care Medicine
Background Persistent vasopressor requirements are a common reason for delayed liberation from the intensive care unit (ICU) and adjunct oral agents are sometimes used to hasten time to vasopressor discontinuation.
Andrew J. Webb, Gianna Lh Casal, Kelly A. Newman, J. Culshaw, Kalynn A. Northam, Edmond Solomon, Sarah M Beargie, Riley Johnson, Natasha D Lopez, Bryan D Hayes, Russel J Roberts   +10 more
semanticscholar   +1 more source

Droxidopa for Symptomatic Neurogenic Hypotension

Cardiology in Review, 2017
Droxidopa is a first-in-class, orally available, synthetic amino acid precursor of norepinephrine that received accelerated Food and Drug Administration approval in February 2014 after Orphan Drug status for a debilitating condition known as symptomatic neurogenic orthostatic hypotension.
openaire   +3 more sources

Droxidopa for the treatment of neurogenic orthostatic hypotension in neurodegenerative diseases

Expert Opinion on Pharmacotherapy, 2019
L-threo-3,4-dihydroxyphenylserine (droxidopa), a pro-drug metabolized to norepinephrine in nerve endings and other tissues, has been commercially available in Japan since 1989 for treating orthostatic hypotension symptoms in Parkinson's disease (PD) patients with a Hoehn & Yahr stage III rating, as well as patients with Multiple System Atrophy (MSA ...
Santiago Pérez-Lloret, Cecilia Quarracino, Matilde Otero-Losada, Olivier Rascol   +3 more
openaire   +4 more sources

Droxidopa approved for neurogenic orthostatic hypotension

American Journal of Health-System Pharmacy, 2014
Droxidopa, a synthetic amino acid precursor of norepinephrine, has been approved as oral therapy for the treatment of neurogenic orthostatic hypotension, FDA and Chelsea Therapeutics announced on February 18.
openaire   +2 more sources

L-dihydroxyphenylserine (Droxidopa) in the treatment of orthostatic hypotension

Clinical Autonomic Research, 2008
Neurogenic orthostatic hypotension is a cardinal feature of generalised autonomic failure and commonly is the presenting sign in patients with primary autonomic failure. Orthostatic hypotension can result in considerable morbidity and even mortality and is a major management problem in disorders such as pure autonomic failure, multiple system atrophy ...
Christopher J. Mathias, Christopher J. Mathias   +1 more
openaire   +3 more sources

Exploration and evaluation of adverse event signals of droxidopa based on the FAERS database.

Expert Opinion on Drug Safety
BACKGROUND This study aims to utilize the FDA's Adverse Event Reporting System (FAERS) for data analysis to explore the potential adverse events associated with Droxidopa in real-world settings, thereby providing reference information for clinical ...
Xinnan Chen, Haohao Zhu, Ying Jiang, Man Tian   +3 more
semanticscholar   +1 more source

A quality by design (QbD) strategy for developing and validating Droxidopa in API and formulation using an RP-HPLC procedure ensuring regulatory compliance

Analytical Chemistry Letters
Background: Droxidopa, a prodrug for neurogenic orthostatic hypotension, requires precise quality analysis. RP-HPLC is valued for its sensitivity and reliability in pharmaceutical quality control, but traditional methods are time-consuming and lack ...
Sandhya Madhuri Maddala, Ravi Parimi, Pravallika K Elvina   +2 more
semanticscholar   +1 more source

DBH deficiency in an elderly patient: efficacy and safety of chronic droxidopa

Clinical Autonomic Research, 2010
We describe the effects of chronic droxidopa in a patient with Dopamine beta-hydroxylase deficiency diagnosed at the age of 73. Investigations were performed to assess sympathetic activity (MIBG scintigraphy, catecholamines) and cardiovascular droxidopa safety.
P. Massabuau, M. Galinier, R. Cagnac, Fabien Despas, M. Berry, Jean-Michel Senard, Jean-Michel Senard, Jean-Michel Senard, A. Pathak, A. Pathak, A. Pathak, E. Liozon   +11 more
openaire   +3 more sources

Simultaneous determination of droxidopa and carbidopa using a carbon nanotubes paste electrode

Sensors and Actuators B: Chemical, 2013
Abstract A novel carbon paste electrode modified with carbon nanotube and 5-amino-2’-ethyl -biphenyl-2-ol (5AEB) was fabricated. The electrochemical study of the modified electrode, as well as its efficiency for electrocatalytic oxidation of droxidopa and carbidopa, is described. Cyclic voltammetry was used to investigate the redox properties of this
Mohammad Ali Taher, Somayeh Tajik, Hadi Beitollahi   +2 more
openaire   +2 more sources